2019 Medicinal Chemistry Reviews

Volume 54, Chapter 22
To Market, to Market—2018: Small Molecules
Erika Araujo, Marie-Gabrielle Braun, Peter S. Dragovich, Antonella Converso, Philippe G. Nantermet, Anthony J. Roecker, T. G. Murali Dhar, Pamela Haile, Anna Hurtley, J. Robert Merritt, Kevin M. Peese

1. Amifampridine (Lambert-Eaton myasthenic syndrome)
2. Apalutamide (anticancer)
3. Avatrombopag (chronic liver disease)
4. Baloxavir Marboxil (antiviral)
5. Bictegravir (antiviral)
6. Binimetinib (anticancer)
7. Cannabidiol (seizures)
8. Dacomitinib (anticancer)
9. Doravirine (antiviral)
10. Duvelisib (anticancer)
11. Elagolix (endometriosis)
12. Elobixibat (constipation)
13. Encorafenib (anticancer)
14. Eravacycline (antibacterial)
15. Evocalcet (hyperparathyroidism)
16. Fosravuconazole (antifungal)
17. Fostamatinib (thrombocytopenia)
18. Fruquintinib (anticancer)
19. Gilteritinib (anticancer)
20. Glasdegib (anticancer)
21. Ivosidenib (anticancer)
22. Larotrectinib (anticancer)
23. Lofexidine (opiate withdrawal)
24. Lorlatinib (anticancer)
25. Moxidectin (onchocerciasis)
26. Omadacycline (antibacterial)
27. Omidenepag (glaucoma)
28. Plazomicin (antibacterial)
29. Plitidepsin (anticancer)
30. Prucalopride (constipation)
31. Pyrotinib (anticancer)
32. Revefenacin (chronic obstructive pulmonary disease)
33. Rifamycin (antibacterial)
34. Roxadustat (antianemic)
35. Sarecycline (antibacterial)
36. Stiripentol (Dravet syndrome)
37. Tafenoquine (malaria)
38. Talazoparib (anticancer)
39. Tecovirimat (antiviral)
40. Tegoprazan (antacid)
41. Tezacaftor (cystic fibrosis)
42. Vibegron (overactive bladder)

To purchase a copy of this chapter, go to our secure e-commerce site.

ACS Division of Medicinal Chemistry

Webmaster:  secretary@acsmedchem.org